Please login to the form below
Marathon Pharma
This page shows the latest Marathon Pharma news and features for those working in and with pharma, biotech and healthcare.
Pfizer abandons antibody for Duchenne
The big pharma company halted two trials of the anti-myostatin antibody, which is designed to build muscle mass and strength. ... At the moment these are the only two drugs available to treat the underlying dystrophin gene mutation in some DMD patients,
Latest news
-
Mallinckrodt doses first patient in muscular dystrophy trial
but was rejected in the US, and novel steroid Emflaza (deflazacort) from Marathon Pharma.
-
Marathon pauses Emflaza launch amid pricing furore
In response, Marathon has said it is "pausing its commercialisation plans" for Emflaza while it meets with the DMD community. ... premiums. Sanders and Cummings say Marathon's action is "an indictment of a system that allows drug companies to engage in
-
FDA approves first steroid for Duchenne muscular dystrophy
Marathon Pharma’s Emflaza is first approved to treat all genetic forms of the condition. ... The FDA has cleared a second drug for Duchenne muscular dystrophy, giving the green light to Marathon Pharma's corticosteroid Emflaza for patients aged five or
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
A marathon and a sprint
It seems some pharma companies are not quite out of the starting blocks. ... Pharma’s CX marathon involves multiple participants; prescribers, policy-makers, regulators, payers, patients, carers and, as the prevention agenda gathers pace, ‘healthy’
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
